Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.

Nat Genet

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA.

Published: March 2004

AI Article Synopsis

  • Chemical genomics involves creating diverse small molecule collections to influence cellular behavior, but current testing methods are often inconsistent.
  • A new method called gene expression-based high-throughput screening (GE-HTS) uses gene expression profiles as indicators of cellular states to improve the process.
  • In testing 1,739 compounds for their ability to induce differentiation in acute myeloid leukemia cells, 8 compounds were found to effectively promote differentiation, showing the potential of GE-HTS for chemical screening.

Article Abstract

Chemical genomics involves generating large collections of small molecules and using them to modulate cellular states. Despite recent progress in the systematic synthesis of structurally diverse compounds, their use in screens of cellular circuitry is still an ad hoc process. Here, we outline a general, efficient approach called gene expression-based high-throughput screening (GE-HTS) in which a gene expression signature is used as a surrogate for cellular states, and we describe its application in a particular setting: the identification of compounds that induce the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we identified 8 that reliably induced the differentiation signature and, furthermore, yielded functional evidence of bona fide differentiation. The results indicate that GE-HTS may be a powerful, general approach for chemical screening.

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng1305DOI Listing

Publication Analysis

Top Keywords

gene expression-based
8
expression-based high-throughput
8
cellular states
8
high-throughput screeningge-hts
4
screeningge-hts application
4
application leukemia
4
differentiation
4
leukemia differentiation
4
differentiation chemical
4
chemical genomics
4

Similar Publications

Background: Breast cancer is a critical threat to human health, and effective targeted agents showing lower systemic toxicity are still lacking. Therefore, exploring new potent therapeutic candidates with a broader safety margin is warranted. Alternative medicine, which has historically been used in traditional Chinese medicine, has played an increasingly prominent role in this area of research.

View Article and Find Full Text PDF

Graph convolution networks model identifies and quantifies gene and cancer specific transcriptome signatures of cancer driver events.

Comput Biol Med

December 2024

Gaffin Center for Neuro-Oncology, Sharett Institute for Oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel; The Wohl Institute for Translational Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel. Electronic address:

Background: The identification and drug targeting of cancer causing (driver) genetic alterations has seen immense improvement in recent years, with many new targeted therapies developed. However, identifying, prioritizing, and treating genetic alterations is insufficient for most cancer patients. Current clinical practices rely mainly on DNA level mutational analyses, which in many cases fail to identify treatable driver events.

View Article and Find Full Text PDF

Targeted gene delivery to vascular smooth muscle cells (VSMCs) could prevent or improve a variety of diseases affecting the vasculature and particularly the aorta. Thus, we aimed to develop a delivery vector that efficiently targets VSMCs. We selected engineered adeno-associated virus (AAV) capsids from a random AAV capsid library and tested the top enriched motifs in parallel screening through individual barcoding.

View Article and Find Full Text PDF

Historically, CLL prognostication relied on disease burden, reflected in clinical stage. Later, chromosome abnormalities and genomics suggested several CLL subtypes which were aligned with response to therapy. Gene expression profiling data identified pathways associated with CLL progression.

View Article and Find Full Text PDF

Background/objectives: High-grade serous carcinomas (HGSCs) are highly heterogeneous tumors, both among patients and within a single tumor. Differences in molecular mechanisms significantly describe this heterogeneity. Four molecular subtypes have been previously described by the Cancer Genome Atlas Consortium: differentiated, immunoreactive, mesenchymal, and proliferative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!